Candida Infection Testing Market Report 2026

The candida infection testing market size has grown strongly in recent years. It will grow from $16.72 billion in 2025 to $17.8 billion in 2026 at a compound annual growth rate (CAGR) of 6.4%. The growth in the historic period can be attributed to increasing incidence of fungal infections, growth in immunocompromised patient populations, expansion of hospital diagnostic services, adoption of culture-based fungal testing, rising awareness of antifungal resistance.

The candida infection testing market size is expected to see strong growth in the next few years. It will grow to $22.56 billion in 2030 at a compound annual growth rate (CAGR) of 6.1%. The growth in the forecast period can be attributed to increasing demand for rapid fungal diagnostics, rising adoption of molecular and microbiome testing, expansion of point-of-care fungal testing, growing investments in infectious disease diagnostics, increasing focus on personalized antifungal therapy. Major trends in the forecast period include increasing adoption of molecular candida detection methods, rising use of rapid naat-based testing, growing integration of microbiome analysis, expansion of hospital-based fungal diagnostics, enhanced focus on early fungal infection identification.

The rising incidence of yeast infections is expected to drive growth in the candida infection testing market in the coming years. Yeast infections are fungal infections caused by the overgrowth of candida, commonly affecting the mouth, genitals, and skin, often resulting in itching, redness, and discomfort. These infections are typically caused by an imbalance in the body’s natural bacteria, weakened immune systems, or hormonal changes. Candida infection testing is used to accurately diagnose candida overgrowth, enabling healthcare providers to confirm infections and guide appropriate treatment. For example, in May 2025, the UK Health Security Agency, a UK-based public health organization, reported that bloodstream infections caused by yeast in England increased by 4% in 2024 compared with 2023, rising from 2,170 to 2,247 cases, and the rate increased from 3.8 to 3.9 per 100,000 population during the same period. Consequently, the growing incidence of yeast infections is expected to fuel the candida infection testing market.

Key players in the candida infection testing market are developing innovative technological solutions, such as fully automated PCR rapid tests for detecting candida, to enhance diagnostic accuracy and improve patient outcomes. A fully automated PCR rapid test uses polymerase chain reaction (PCR) technology to quickly and accurately identify the presence of Candida species in clinical samples. For instance, in May 2024, Bosch Healthcare Solutions GmbH, a Germany-based medical technology manufacturer, launched a PCR test for Candida auris detection on the Vivalytic platform, offering fully automated, rapid testing within an hour at the point of care. This advanced test enables prompt screening and contrasts with traditional culture methods, which require one to three days in centralized laboratories, delaying diagnosis and treatment. Designed for clinical settings, the test is particularly valuable for high-risk patients, allowing timely diagnosis and intervention to manage the serious health risks associated with C. auris infections.

In February 2024, Bruker Corporation, a US-based provider of scientific instruments and analytical solutions, completed its acquisition of ELITechGroup for approximately €870 million (around $942 million) in cash. This acquisition strengthens Bruker’s portfolio in molecular diagnostics and infectious disease testing by integrating ELITech’s innovative technologies and expertise. ELITechGroup, based in France, is a global leader in the in vitro diagnostics (IVD) industry.

Major companies operating in the candida infection testing market are Thermo Fisher Scientific Inc., Abbott Laboratories, Siemens Healthineers AG, Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Hologic Inc., bioMérieux SA, Bio-Rad Laboratories Inc., Bruker Corporation, QIAGEN N.V., Cepheid, Randox Laboratories Ltd., Meridian Bioscience Inc., DiaSorin S.p.A., Sekisui Diagnostics LLC, Enzo Biochem Inc., T2 Biosystems Inc., Aidian Oy, SafeCare LLC, CHROMagar, HK Biotek Inc., Health Testing Centers LLC, Accesa Labs LLC, Private MD Labs LLC.

North America was the largest region in the candida infection testing market in 2025. The regions covered in the candida infection testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the candida infection testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the candida infection testing market by increasing costs of imported molecular testing kits, reagents, diagnostic instruments, and laboratory consumables. Hospitals and laboratories in North America and Europe are most affected due to reliance on imported fungal diagnostic technologies, while Asia-Pacific faces cost pressure on reagent supply chains. These tariffs are increasing testing costs and slowing diagnostic expansion in smaller facilities. However, they are also encouraging local production of fungal diagnostic reagents, regional laboratory supply manufacturing, and investment in domestic infectious disease testing capabilities.

The candida infection testing market research report is one of a series of new reports that provides candida infection testing market statistics, including candida infection testing industry global market size, regional shares, competitors with a candida infection testing market share, detailed candida infection testing market segments, market trends and opportunities, and any further data you may need to thrive in the candida infection testing industry. This candida infection testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Candida infection testing involves diagnostic procedures used to detect the presence of candida species, fungi that can cause infections in different parts of the body. These tests help identify the type and severity of the infection, enabling healthcare providers to determine appropriate treatment strategies.

The main types of candida infection testing include invasive candidiasis and candidemia. Invasive candidiasis is a serious fungal infection that occurs when candida enters the bloodstream and spreads to organs such as the heart, brain, eyes, bones, and other tissues. Testing methods include vaginal pH tests, nucleic acid amplification testing (NAAT), and microbiome analysis, and are applied across various healthcare settings, including hospitals and diagnostic laboratories.

The candida infection testing market includes revenues earned by entities by providing services such as diagnostic testing services, culture testing, consultation services, training and support, and microscopic examination. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.